Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Gomez Simmonds, Angela ^a   Stump, Stephania ^a   Giddins, Marla J ^a   Annavajhala, Medini K ^a   Uhlemann, Anne Catrin ^a  

^a Department of Medicine   (United States)

Author keywords

Carbapenem resistance; Enterobacteriaceae; Imipenem relebactam

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE KPC 2; BETA LACTAMASE KPC 3; BETA LACTAMASE KPC 4; BETA LACTAMASE NDM 1; CARBAPENEMASE; CILASTATIN PLUS IMIPENEM; IMIPENEM; PORIN; RELEBACTAM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; MK-7655;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GENE DISRUPTION; GENE MUTATION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERRATIA MARCESCENS; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; ENTEROBACTERIACEAE; IMIPENEM; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 85052021811     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00573-18     Document Type: Article

References (40)

1. CDC. 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA.
2. van Duin D, Doi Y. 2017. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8:460–469. https://doi.org/10.1080/21505594.2016.1222343.
3. Thaden JT, Pogue JM, Kaye KS. 2017. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 8:403–416. https://doi.org/10.1080/21505594.2016.1207834.
4. Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, Imbriglio J, Young K, Park YW, Ogawa A, Raghoobar S, Hairston N, Painter RE, Wisniewski D, Scapin G, Fitzgerald P, Sharma N, Lu J, Ha S, Hermes J, Hammond ML. 2014. Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R). Bioorg Med Chem Lett 24:780–785. https://doi.org/10.1016/j.bmcl.2013.12.101.
5. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290. https://doi.org/10.1093/jac/dkt178.
6. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029–5031. https://doi.org/10.1128/AAC.00830-15.
7. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF. 2017. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). Antimicrob Agents Chemother 61:e02209-16. https://doi.org/10.1128/AAC.02209-16.
8. Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF. 2017. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015—results from the SMART global surveillance program. Diagn Microbiol Infect Dis 88: 171–176. https://doi.org/10.1016/j.diagmicrobio.2017.02.018.
9. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642-17. https://doi.org/10.1128/AAC.00642-17.
10. Bush K. 2015. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483–493. https://doi.org/10.1016/j.ijantimicag.2015.08.011.
11. Pecora ND, Li N, Allard M, Li C, Albano E, Delaney M, Dubois A, Onder-donk AB, Bry L. 2015. Genomically informed surveillance for carbapenem-resistant Enterobacteriaceae in a health care system. mBio 6:e01030. https://doi.org/10.1128/mBio.01030-15.
12. KPC-3 in the upper midwestern United States. Antimicrob Agents Chemother 59:7723–7734. https://doi.org/10.1128/AAC.01291-15.
13. Gomez-Simmonds A, Hu Y, Sullivan SB, Wang Z, Whittier S, Uhlemann AC. 2016. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007–14. J Antimicrob Chemother 71:2351–2353. https://doi.org/10.1093/jac/dkw132.
14. Chavda KD, Chen L, Fouts DE, Sutton G, Brinkac L, Jenkins SG, Bonomo RA, Adams MD, Kreiswirth BN. 2016. Comprehensive genome analysis of carbapenemase-producing Enterobacter spp.: new insights into phylogeny, population structure, and resistance mechanisms. mBio 7:e02093-16. https://doi.org/10.1128/mBio.02093-16.
15. Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, Perez F. 2017. Carbapenem-resistant Enterobacter cloacae in patients from the US Veterans Health Administration, 2006–2015. Emerg Infect Dis 23:878–880. https://doi.org/10.3201/eid2305.162034.
16. Trecarichi EM, Tumbarello M. 2017. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence 8:470–484. https://doi.org/10.1080/21505594.2017.1292196.
17. Weindorf H, Schmidt H, Martin HH. 1998. Contribution of overproduced chromosomal beta-lactamase and defective outer membrane porins to resistance to extended-spectrum beta-lactam antibiotics in Serratia marcescens. J Antimicrob Chemother 41:189–195. https://doi.org/10.1093/jac/41.2.189.
18. Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K. 2010. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. Antimicrob Agents Chemother 54:5057–5061. https://doi.org/10.1128/AAC.00768-10.
19. Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ, Shi Q, Whittier S, Gomez-Simmonds A, Uhlemann AC. 2017. Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC -lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 61:e00276-17. https://doi.org/10.1128/AAC.00276-17.
20. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multi-centre study. J Antimicrob Chemother 70:2133–2143. https://doi.org/10.1093/jac/dkv086.
21. Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, van Duin D, Kreiswirth BN, Kaye KS, Bonomo RA. 2018. Relebactam is a potent inhibitor of the KPC-2 -lactamase and restores the susceptibility of imipenem against KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother 62:e00174-18. https://doi.org/10.1128/AAC.00174-18.
22. Garcia-Fernandez A, Villa L, Carta C, Venditti C, Giordano A, Venditti M, Mancini C, Carattoli A. 2012. Klebsiella pneumoniae ST258 producing KPC-3 identified in Italy carries novel plasmids and OmpK36/OmpK35 porin variants. Antimicrob Agents Chemother 56:2143–2145. https://doi.org/10.1128/AAC.05308-11.
23. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/ tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 63:234–241. https://doi.org/10.1093/cid/ciw243.
24. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW. 2018. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18:285–295. https://doi.org/10.1016/S1473-3099(17)30747-8.
25. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. 2016. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380–1389. https://doi.org/10.1093/cid/ciw133.
26. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673. https://doi.org/10.1016/S1473-3099(16)30004-4.
27. Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW. 2017. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents 49:579–588. https://doi.org/10.1016/j.ijantimicag.2017.01.010.
28. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. 2016. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754–762. https://doi.org/10.1093/cid/ciw378.
29. Stone GG, Bradford PA, Yates K, Newell P. 2017. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a phase 3 clinical trial programme for the treatment of complicated urinary tract infections. J Antimicrob Chemother 72:1396–1399. https://doi.org/10.1093/jac/dkw561.
30. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Jr, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171. https://doi.org/10.1093/cid/cix783.
31. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
32. KPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 62:e02101-17. https://doi.org/10.1128/AAC.02101-17.
33. CLSI. 2016. Performance standards for antimicrobial susceptibility testing, M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
34. Gomez-Simmonds A, Annavajhala MK, Wang Z, Macesic N, Hu Y, Giddins MJ, O’Malley A, Toussaint NC, Whittier S, Torres V, Uhlemann AC. 2018. Carbapenem-resistant Enterobacter cloacae complex demonstrates mul-tifactorial genomic adaptation to nosocomial environment. mBio 9:e00542-18. https://doi.org/10.1128/mBio.00542-18.
35. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 6:90. https://doi.org/10.1186/s13073-014-0090-6.
36. Adiri RS, Gophna U, Ron EZ. 2003. Multilocus sequence typing (MLST) of Escherichia coli O78 strains. FEMS Microbiol Lett 222:199–203. https://doi.org/10.1016/S0378-1097(03)00295-7.
37. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43:4178 – 4182. https://doi.org/10.1128/JCM.43.8.4178-4182.2005.
38. Miyoshi-Akiyama T, Hayakawa K, Ohmagari N, Shimojima M, Kirikae T. 2013. Multilocus sequence typing (MLST) for characterization of Enterobacter cloacae. PLoS One 8:e66358. https://doi.org/10.1371/journal.pone.0066358.
39. Bai L, Xia S, Lan R, Liu L, Ye C, Wang Y, Jin D, Cui Z, Jing H, Xiong Y, Bai X, Sun H, Zhang J, Wang L, Xu J. 2012. Isolation and characterization of cytotoxic, aggregative Citrobacter freundii. PLoS One 7:e33054. https://doi.org/10.1371/journal.pone.0033054.
40. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 58:212–220. https://doi.org/10.1128/AAC.01310-13.